Find the Perfect Plan for Your Investment Journey
Latest price
52 Week Range
$0.77 - $4.08
Next Earnings Date
May 12 2025
Next Earnings Date
May 12 2025
Latest price
Market Cap | $286.24M |
EV | $166.16M |
Shares Outstanding | 138.28M |
Beta | 1.19 |
Analyst Rating | BUY |
Analyst Target Price | $13.10 |
P/E 2025E | - |
P/Revenue 2025E | 180.44x |
Revenue | - |
EPS | 35.00% |
Operating Cash Flow | -31.60% |
Free Cash Flow | -27.70% |
Revenue | 424.00% |
EPS | 16.50% |
Operating Cash Flow | 2.60% |
Free Cash Flow | -5.10% |
Gross Margin 2025E | 0.00% |
Net Profit Margin 2025E | - |
ROE 2025E | - |
ROCE 2024 | -36.07% |
DPS 2025E | - |
Payout Ratio 2025E | - |
Div. Yield 2025E | - |
DPS Last 3Y CAGR | - |
Price
%
1M
3M
6M
1Y
3Y
5Y
Compass Therapeutics, Inc.
CMPX
Sector
Healthcare
Industry
Biotechnology
CEO
Schuetz, Thomas
Employees
35
Website
www.compasstherapeutics.comIPO Date
2021-04-05
Headquarters
80 Guest Street, Suite 601, Boston, Massachusetts, 02135, United States
COMPANY
NEWSLETTER
© Copyright 2025, All Rights Reserved